Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)
15 Maggio 2023 - 3:00PM
Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic
and synthetic biology solutions, today announced they will be
showcasing their benchtop automation solutions for DNA and mRNA
synthesis at Protein Engineering Summit (PEGS Boston 2023) which
begins today in Boston, Massachusetts. Daniel Gibson, Ph.D., CTO
and Co-founder of Telesis Bio and the Telesis Bio team will be
discussing Telesis Bio’s transformative solutions for addressing
synthesis bottlenecks in discovery workflows and enabling rapid
candidate screening and evaluation.
Telesis Bio will present in two sessions; Jyotsna Venugopal,
Ph.D., Director of Product Marketing, will present “Automated
solutions for overcoming synthesis bottlenecks in CAR-T cell
therapy workflows” on Tuesday, May 16, and Ankita Das, Ph.D.,
Senior Product Manager, will present “Sequence in, mRNA out. A new
paradigm to accelerate discovery of mRNA vaccines and therapeutics”
in the poster session.
The award winning BioXp® system and associated BioXp® De novo
and Select synthesis kits enable on-demand and automated synthesis
of DNA and mRNA beginning from a customer’s sequence or own linear
DNA or plasmid DNA, overnight and at the push of a button. The
system enables researchers to optimize their discovery workflows by
building their construct of interest in days, rather than weeks or
months of alternative methods.
“By enabling researchers to overcome the bottleneck created by
long lead times to build or buy their DNA or mRNA, they can more
efficiently integrate their design-build-test cycles and quickly
advance their discovery workflows. We believe our BioXp® system can
empower researchers to accelerate drug discovery, particularly in
the areas of mRNA therapeutics and vaccines, Antibody discovery and
engineering and Cell-Based immunotherapies,” said Daniel Gibson,
Ph.D., CTO and Co-founder of Telesis Bio.
For more information on the BioXp® system to automate DNA and
mRNA synthesis please visit:
DNA synthesis on the BioXp system:
https://telesisbio.com/workflows/synthetic-dna/
mRNA synthesis on the BioXp system:
https://telesisbio.com/workflows/synthetic-mrna/
About Telesis BioTelesis Bio is empowering
scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Telesis Bio is enabling rapid, accurate and
reproducible writing of DNA and mRNA for numerous downstream
markets. The award-winning BioXp® system consolidates, automates,
and optimizes the entire synthesis, cloning and amplification
workflow. As a result, it delivers virtually error-free synthesis
of DNA and RNA at scale within days and hours instead of weeks or
months. Scientists around the world are using the technology in
their own laboratories to accelerate the design-build-test paradigm
for novel, high-value products for precision medicine, biologics
drug discovery, vaccine and therapeutic development, genome
editing, and cell and gene therapy. Telesis Bio is a public company
based in San Diego. For more information, visit
www.telesisbio.com.
Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp
are trademarks of Telesis Bio Inc.
Forward-Looking Statements This press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements and guidance regarding Telesis Bio’s future
financial performance as well as statements regarding the future
release and success of new and existing products and services. Such
statements are based on current assumptions that involve risks and
uncertainties that could cause actual outcomes and results to
differ materially. These risks and uncertainties, many of which are
beyond our control, include risks described in the section entitled
Risk Factors and elsewhere in our Quarterly Report on Form 10-Q,
which was filed with the Securities and Exchange Commission on
November 11, 2022. These forward-looking statements speak only as
of the date hereof and should not be unduly relied upon. Telesis
Bio disclaims any obligation to update these forward-looking
statements.
Contact:Jen CarrollVice President of Investor
Relationsjen.carroll@telesisbio.com
Grafico Azioni Telesis Bio (NASDAQ:TBIO)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Telesis Bio (NASDAQ:TBIO)
Storico
Da Set 2023 a Set 2024